EAN 2026 | An update on the TEMPO-2 trial: the potential of tavapadon to improve outcomes in PD
Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, gives an update on the TEMPO-2 trial (NCT04223193), which is evaluating tavapadon for early Parkinson’s disease (PD). Prof. Antonini notes that tavapadon is the first D1-receptor agonist to demonstrate improvements in mobility and functionality in both early and advanced PD. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For many years we thought that dopamine agonists would be effective only if they acted on the dopamine D2 receptor subgroup. But in recent years we have learned that also D1 is very important in Parkinson’s functionality and mobility. Tavapadon is the first D1 agonist that comes to clinical use. The data are very solid and are clearly showing that there is a good improvement in mobility and functionality in both early and advanced Parkinson patients...
For many years we thought that dopamine agonists would be effective only if they acted on the dopamine D2 receptor subgroup. But in recent years we have learned that also D1 is very important in Parkinson’s functionality and mobility. Tavapadon is the first D1 agonist that comes to clinical use. The data are very solid and are clearly showing that there is a good improvement in mobility and functionality in both early and advanced Parkinson patients. The main advantage of Tavapadon based on its pharmacodynamic profile and the action on D1, is that it is less likely to trigger behavioral complications like pramipexole or ropinirole. So we don’t expect, and we have not seen so far, significant risk of impulse control. And surprisingly enough, even if animal data indicated that D1 agonism may induce dyskinesias, patients who are on tavapadon, even in the advanced stage, don’t develop much dyskinesias. And the risk of dyskinesias stays pretty low in the early and in the advanced phase. So I think that tavapadon may represent a new kind of dopamine agonist that will allow us to use them much more safely in early patients, complementing the effect of levodopa and maybe COMT inhibition in Parkinson’s disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
